Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and testing services to the global nutraceuticals, cosmeceuticals, food/beverage, biotherapeutics, agrochemical, and other industries has received “powerful scientific validation” through an independent peer-reviewed scientific study. According to the announcement, globally renowned cannabis/natural products researcher Dr. Mahmoud A. ElSohly, who is with ElSohly Laboratories Inc., conducted studies indicating that PBIO’s UltraShear(TM) nanoemulsified CBD, or Nano CBD, achieved “unparalleled efficiency of oral-GI CBD absorption and systemic bioavailability of active CBD.”

The company noted that ElSohly’s research verifies that PBIO’s UltraShear Technology platform allows oil-soluble active molecules, such as CBD, to be prepared into premium quality nanoemulsions of “vanishingly tiny” oil droplets in water, enabling those molecules to deliver unprecedented absorption speed and bioavailability when compared to current technologies. ElSohly’s research was published earlier this week in the “Medical Cannabis and Cannabinoids” journal. ElSohly noted that his team was surprised by the results of the oral-GI ingestion of UltraShear Nano CBD, which looked “almost like instant absorption.” PBIO’s UltraShear Nano-CBD is a preservative-free, “green/clean”-labeled, sterile-filtered and vialed, plant-based, highly bioavailable organic product. “Delivering scientifically proven breakthroughs in CBD absorption and bioavailability, UltraShear processing allows our partners to bring vastly superior products to market that give their customers more of what they are paying for,” said PBIO director of sales and marketing John Hollister in the press release. “Consumers will love the blazing fast initial benefits and the four times bioavailability that deliver a dramatically improved consumer experience.”

To view the full press release, visit https://ibn.fm/pgqfH

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. PBIO’s first patented enabling technology platform, Pressure Cycling Technology (“PCT”), is used to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics and counterbioterrorism applications. The company’s acquisition of the BaroFold(TM) patented technology platform in 2017 allowed it to offer important new biopharma contract services and GMP manufacturing equipment to this enormous market sector. Most recently, the company has also developed the commercially scalable and high-efficiency pressure-based UltraShear Technology(TM) platform, which allows for the production of stable and precisely controlled nanoemulsions of otherwise immiscible oil and water components. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN